Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Eli Lilly strikes again in weight-loss drugs fight
Americas
Eli Lilly strikes again in weight-loss drugs fight
Texas pharmacy accused of mass-producing unapproved tirzepatide drugs | Lilly claimed pharmacy falsely marketed copycat versions of Mounjaro and Zepbound as safe and effective | It warned of “conducting a mass testing experiment on consumers without safety controls or informed consent”.   29 July 2025
Novartis moves to block cancer drug generic in US
Americas
Novartis moves to block cancer drug generic in US
Swiss pharma giant files patent infringement lawsuit to stop Teva’s generic Mekinist launch in US | Follows European Patent Office revocation of key patent after Teva proved lack of inventive step.   28 July 2025
UPC hands rare default win to Insulet, bans insulin pump in EU
Europe
UPC hands rare default win to Insulet, bans insulin pump in EU
Court delivers default judgment dismissing EOFlow’s patent revocation claim | Dispute escalates following EOFlow’s refusal to post security amid financial concerns | Following detailed analysis, it upholds infringement claims ordering sales ban across 17 countries.   24 July 2025
Europe
GSK loses appeal over purple inhaler TM in Europe
Design and colour combination deemed ‘too common’ in the pharma sector for protection | Court says trademarks must be distinctive across the EU, not just individual countries.   24 July 2025
Europe
Astellas defends Xtandi patent as court rejects generics’ appeal
Court of Appeal backs Astellas in UK patent fight over prostate cancer drug | Generics’ challenge fails as judges warn on expert evidence and hindsight bias | Court urges caution when instructing expert witnesses in obviousness cases.   23 July 2025
Americas
Jury sides with Allergan in $56M Botox tech feud
$56M awarded to AbbVie unit in Delaware patent fight over Botox treatment | US Botox sales reportedly grew to over $4.4 billion last year, while trade secrets lawsuit against rival continues.   22 July 2025
Europe
Startups toolkit: Why investors want more than patents
For startups, getting a drug to market is a marathon but founders need to think beyond filing patents to win over investors, Marisa Woutersen explores how they can succeed.   10 July 2025
Americas
Startup challenges rival over brain monitoring tech at ITC
California medical device company sues rival at the ITC and in Delaware court over “copycat” brain monitoring system launch in May | Ceribell accuses competitor of “a history of willful patent infringement”.   9 July 2025
Americas
Bayer, Orion take on Indian generic over $117bn drug
German and Finnish pharma giants sue Indian rival in Delaware court | Dispute centres on generic bid for prostate cancer blockbuster | Suit follows leadership shakeup at Bayer.   8 July 2025
Europe
Sanofi successfully challenges rare disease patent in Europe
French biopharma giant overturns German rival’s patent at the European Patent Office | Revocation based on insufficient disclosure of antibody production | Appeal focused on detection method claims and biomarker specificity.   1 July 2025

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.